Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
The American Journal of Pathology|February 11, 2014
Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanismsAlessandra Decio, Giulia Taraboletti, Veronica Patton, et al.
Cell Death & Disease|March 21, 2026
TSP-1 interaction with RANK and OPG: implications for bone remodeling and osteolytic bone metastasisLaura Carminati, Fabio Sangalli, Chiara Urbinati, et al.
Plos One|May 19, 2012
Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small moleculeKatiuscia Pagano, Rubben Torella, Chiara Foglieni, et al.
Neoplasia (New York, N.Y.)|September 29, 2012
Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapiesKatiuscia Bonezzi, Dorina Belotti, Brian J North, et al.
Connective Tissue Research|May 7, 2015
Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenograftsDenise Pinessi, Paola Ostano, Patrizia Borsotti, et al.
Cancer Chemotherapy and Pharmacology|August 28, 2013
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinibMassimo Zucchetti, Katiuscia Bonezzi, Roberta Frapolli, et al.
Plos One|January 7, 2011
Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cellsCristina Belgiovine, Roberta Frapolli, Katiuscia Bonezzi, et al.
The International Journal of Biochemistry & Cell Biology|November 13, 2007
Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domainBarbara Margosio, Marco Rusnati, Katiuscia Bonezzi, et al.
Molecular Cancer Therapeutics|December 29, 2012
The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenograftsEzia Bello, Giulia Taraboletti, Gennaro Colella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2002
Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivativeGiulia Taraboletti, Gianluca Micheletti, Monica Rieppi, et al.
Pageof 6